Amphastar Pharmaceuticals (AMPH) saw its stock surge 5.63% in pre-market trading on Tuesday, following two major announcements that have boosted investor confidence in the biopharmaceutical company.
The primary catalyst for the stock's jump is Amphastar's newly inked exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. The deal, announced early Tuesday, grants Amphastar the rights to develop and commercialize three peptide-based therapies in the United States and Canada. These innovative treatments target multiple poorly treated cancers, aim to improve docetaxel's selectivity and bioavailability, and address wet age-related macular degeneration. Amphastar CEO Dr. Jack Zhang emphasized that this partnership significantly enhances their pipeline with potentially best-in-class assets, reinforcing their commitment to transformative patient therapies.
Adding to the positive momentum, Needham has upgraded Amphastar Pharmaceuticals from Hold to Buy, setting a new price target of $36. This vote of confidence from a respected financial institution has further fueled investor enthusiasm. The combination of the licensing deal's potential for long-term growth and the analyst upgrade has created a bullish sentiment around Amphastar, driving the significant pre-market price increase.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.